PRCT PROCEPT BIOROBOTICS CORP

PROCEPT BioRobotics to Report Second Quarter 2023 Financial Results on July 27, 2023

PROCEPT BioRobotics to Report Second Quarter 2023 Financial Results on July 27, 2023

REDWOOD CITY, Calif., July 11, 2023 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2023 before market open on Thursday, July 27, 2023. The Company’s management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.

Investors interested in listening to the conference call may do so by following one of the below links:

  • Webcast link for interested listeners:
  • Dial-in registration for sell-side research analysts:

Live audio of the webcast will be available on the “Investors” section of the Company’s website at: .

An archived recording will be available on the “Investors” section of the Company’s website at: . Each webcast will be available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Investor Contact:

Matt Bacso, CFA

VP, Investor Relations and Business Operations



EN
11/07/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PROCEPT BIOROBOTICS CORP

 PRESS RELEASE

PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler ...

PROCEPT BioRobotics® to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025 SAN JOSE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 37th Annual Piper Sandler Healthcare Conference in New York City. Management is scheduled to present on Tuesday, December 2 at 8:30 a.m. Eastern Time. A live webcast of each event, as well as ...

 PRESS RELEASE

PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and I...

PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2025. Recent Highlights Total revenue of $83.3 million for the third quarter of 2025, an increase of 43% compared to the prior year period in 2024U.S. handpiece and consumables revenue ...

 PRESS RELEASE

PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on...

PROCEPT BioRobotics® to Report Third Quarter 2025 Financial Results on November 4, 2025 SAN JOSE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2025 after market close on Tuesday, November 4, 2025. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by follow...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 16, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch